Ad hoc Rebalancing | Solactive China Biotech Index | July 2019

In the ad hoc rebalance the following composition will be implemented:

3SBIO INC
ANHUI ANKE BIOTECHNOLOGY G-A
BEIGENE LTD-ADR
BEIJING TIANTAN BIOLOGICAL-A
BETTA PHARMACEUTICALS CO L-A
BGI GENOMICS CO LTD-A
CHINA BIOLOGIC PRODUCTS HOLD
GENSCRIPT BIOTECH CORP
HUALAN BIOLOGICAL ENGINEER-A
HUTCHISON CHINA MEDITECH-ADR
INNOVENT BIOLOGICS INC
JIANGSU HENGRUI MEDICINE CO LTD CLASS A
LIVZON PHARMACEUTICAL GROU-A
LUYE PHARMA GROUP LTD
SHANGHAI RAAS BLOOD PRODUC-A
SHENZHEN KANGTAI BIOLOGICA-A
SINO BIOPHARMACEUTICAL LTD ORD
WALVAX BIOTECHNOLOGY CO-A
WUXI APPTEC CO LTD-A
WUXI BIOLOGICS CAYMAN INC